Hybond N Problems
mgruidl at com1.med.usf.edu
Tue Aug 20 17:03:26 EST 1996
sunil shaw wrote:
> Is it okay for a company to change the basic formulation of a product,
> but to market it under the same name? At least if they were to say
> 'new, improved' or something like that, users would have warning
> of potential differences.
After learning of the formulation change, I checked the box and it said
that the membrane was a new formulation. Other conversations with
Amersham, they now say that they will incorporate stronger wording
within the box. I suggested they tell us which protocols are prone to
problems, then if a user decides to do differently it is the users own
fault. The company can always say we warned you not to do it that way.
On another but similar note. I have just repeated some of my northerns
using the Church buffer. No background. I'm convinced.
More information about the Methods